Please assess the completion status of the following clinical trial:

Trial Title: A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of HIV infection.~* Age ≥ 18~* Males and females are eligible. Subjects must agree to practice birth control or abstinence. Females of child-bearing potential must have a negative urine pregnancy within 14 days prior to study entry.~* Adequate baseline organ function including the following laboratory values within 14 days prior to study entry:~* Adequate liver function with ALT, AST and alkaline phosphatase ≤ 5 times upper limit of normal (ULN).~* Total bilirubin ≤ 2.5 mg/dL Creatinine \< 2.3 Serum vitamin B12 level ≥ 200 pg/ml~* Diagnosis of HIVM by a neurologist - defined as:~* - Presence of at least two of the following symptoms:~* - Paresthesias and/or numbness in the lower extremities or in all four limbs; Weakness of the limbs, with predominance in the lower extremities; Unsteady, stiff or uncoordinated gait; Sensation of electrical shock through the back or the legs upon flexion of the neck (L'Hermitte's sign); Stiffness or spasm in the lower extremities; Urinary frequency, urgency, incontinence or retention; Fecal incontinence or retention; Sexual dysfunction with erectile impairment in men;~* - Presence of at least two of the following neurologic signs:~* - Reduction in vibratory or position sensation in the lower extremities; Hyperactive deep tendon reflexes; Abnormal response to plantar stimulation (Babinski sign); Presence of L'Hermitte sign (electrical-type sensation down the back, provoked by flexion of the neck); Weakness in the lower extremities or in all four limbs; Spastic or ataxic gait~* Antiretroviral regimen stable 2 months prior to the entry of the study.~Exclusion Criteria:~* Presence of acute, active, opportunistic infection, except oral thrush, orogenital or rectal herpes and MAI bacteremia within 2 weeks before randomization.~* Evidence of another contributing cause for myelopathy.~* Women who are pregnant, breast-feeding or planning a pregnancy.~* Active abuse of drugs or alcohol, which in the opinion of the investigator would interfere with the subject's ability to comply with the protocol.~* Any neurologic or systemic conditions, which in the opinion of the investigator would interfere with the evaluation of the subject.~* Presence of significant cardiac, pulmonary or renal disease that would place the subject at risk for the fluid and protein load of IVIg.~* History of hypersensitivity to immunoglobulin, or IgA deficiency; Vaccination with live viruses within the past 90 days; Patients receiving IVIg or other immunomodulatory agent (cyclosphosphamide, azathioprine, corticosteroids, tacrolimus, cyclosporine, OKT3, plasma exchange, alpha, beta or gamma interferon) within the past 3 months.~* Patients in whom muscle dynamometry can not be performed for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous Immunoglobulin (Type: EXPERIMENTAL): Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
- Placebo (Type: PLACEBO_COMPARATOR): Saline 2gr/kg over 2 days of saline

Based on this trial design, predict the completion outcome and termination type (if applicable).